Use Actual Body Weight When Calculating Renal Function For Edoxaban

Savaysa (sa-VAYE-sah, edoxaban) will be the fourth new oral anticoagulant (NOAC)...after Pradaxa, Xarelto, and Eliquis.

It's approved for once-daily use in atrial fib and venous thromboembolism (VTE).

But edoxaban has an odd twist when used for A fib. It does NOT work as well as warfarin in patients with NORMAL kidney function.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals